Brought to you by 
Merck pays $102 per share for Cubist
10 Sep 2020
Executive Summary
Merck & Co. Inc. will pay $102 per share (a 36% premium), or $7.8bn, to buy public anti-infective drug company Cubist Pharmaceuticals Inc. The deal also includes the assumption of about $1.1bn in net debt and other considerations.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck pays $102 per share for Cubist
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice